Cargando…
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315922/ https://www.ncbi.nlm.nih.gov/pubmed/35903706 http://dx.doi.org/10.3389/fonc.2022.897280 |
_version_ | 1784754680418533376 |
---|---|
author | Kaufman, Matthew Yan, Xiao-Jie Li, Wentian Ghia, Emanuela M. Langerak, Anton W. Rassenti, Laura Z. Belessi, Chrysoula Kay, Neil E. Davi, Frederic Byrd, John C. Pospisilova, Sarka Brown, Jennifer R. Catherwood, Mark Davis, Zadie Oscier, David Montillo, Marco Trentin, Livio Rosenquist, Richard Ghia, Paolo Barrientos, Jacqueline C. Kolitz, Jonathan E. Allen, Steven L. Rai, Kanti R. Stamatopoulos, Kostas Kipps, Thomas J. Neuberg, Donna Chiorazzi, Nicholas |
author_facet | Kaufman, Matthew Yan, Xiao-Jie Li, Wentian Ghia, Emanuela M. Langerak, Anton W. Rassenti, Laura Z. Belessi, Chrysoula Kay, Neil E. Davi, Frederic Byrd, John C. Pospisilova, Sarka Brown, Jennifer R. Catherwood, Mark Davis, Zadie Oscier, David Montillo, Marco Trentin, Livio Rosenquist, Richard Ghia, Paolo Barrientos, Jacqueline C. Kolitz, Jonathan E. Allen, Steven L. Rai, Kanti R. Stamatopoulos, Kostas Kipps, Thomas J. Neuberg, Donna Chiorazzi, Nicholas |
author_sort | Kaufman, Matthew |
collection | PubMed |
description | Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the heart of the worse outcomes of CLL cases without/few IGHV mutations. A corollary of this conclusion is that M-CLL follow less aggressive clinical courses because somatic IGHV mutations have altered BCR structures and no longer bind stimulatory (auto)antigens and so cannot deliver trophic signals to leukemic B cells. However, the latter assumption has not been confirmed in a large patient cohort. We tried to address the latter by measuring the relative numbers of replacement (R) mutations that lead to non-conservative amino acid changes (Rnc) to the combined numbers of conservative (Rc) and silent (S) amino acid R mutations that likely do not or cannot change amino acids, “(S+Rc) to Rnc IGHV mutation ratio”. When comparing time-to-first-treatment (TTFT) of patients with (S+Rc)/Rnc ≤ 1 and >1, TTFTs were similar, even after matching groups for equal numbers of samples and identical numbers of mutations per sample. Thus, BCR structural change might not be the main reason for better outcomes for M-CLL. Since the total number of IGHV mutations associated better with longer TTFT, better clinical courses appear due to the biologic state of a B cell having undergone many stimulatory events leading to IGHV mutations. Analyses of larger patient cohorts will be needed to definitively answer this question. |
format | Online Article Text |
id | pubmed-9315922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93159222022-07-27 Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia Kaufman, Matthew Yan, Xiao-Jie Li, Wentian Ghia, Emanuela M. Langerak, Anton W. Rassenti, Laura Z. Belessi, Chrysoula Kay, Neil E. Davi, Frederic Byrd, John C. Pospisilova, Sarka Brown, Jennifer R. Catherwood, Mark Davis, Zadie Oscier, David Montillo, Marco Trentin, Livio Rosenquist, Richard Ghia, Paolo Barrientos, Jacqueline C. Kolitz, Jonathan E. Allen, Steven L. Rai, Kanti R. Stamatopoulos, Kostas Kipps, Thomas J. Neuberg, Donna Chiorazzi, Nicholas Front Oncol Oncology Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the heart of the worse outcomes of CLL cases without/few IGHV mutations. A corollary of this conclusion is that M-CLL follow less aggressive clinical courses because somatic IGHV mutations have altered BCR structures and no longer bind stimulatory (auto)antigens and so cannot deliver trophic signals to leukemic B cells. However, the latter assumption has not been confirmed in a large patient cohort. We tried to address the latter by measuring the relative numbers of replacement (R) mutations that lead to non-conservative amino acid changes (Rnc) to the combined numbers of conservative (Rc) and silent (S) amino acid R mutations that likely do not or cannot change amino acids, “(S+Rc) to Rnc IGHV mutation ratio”. When comparing time-to-first-treatment (TTFT) of patients with (S+Rc)/Rnc ≤ 1 and >1, TTFTs were similar, even after matching groups for equal numbers of samples and identical numbers of mutations per sample. Thus, BCR structural change might not be the main reason for better outcomes for M-CLL. Since the total number of IGHV mutations associated better with longer TTFT, better clinical courses appear due to the biologic state of a B cell having undergone many stimulatory events leading to IGHV mutations. Analyses of larger patient cohorts will be needed to definitively answer this question. Frontiers Media S.A. 2022-07-12 /pmc/articles/PMC9315922/ /pubmed/35903706 http://dx.doi.org/10.3389/fonc.2022.897280 Text en Copyright © 2022 Kaufman, Yan, Li, Ghia, Langerak, Rassenti, Belessi, Kay, Davi, Byrd, Pospisilova, Brown, Catherwood, Davis, Oscier, Montillo, Trentin, Rosenquist, Ghia, Barrientos, Kolitz, Allen, Rai, Stamatopoulos, Kipps, Neuberg and Chiorazzi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kaufman, Matthew Yan, Xiao-Jie Li, Wentian Ghia, Emanuela M. Langerak, Anton W. Rassenti, Laura Z. Belessi, Chrysoula Kay, Neil E. Davi, Frederic Byrd, John C. Pospisilova, Sarka Brown, Jennifer R. Catherwood, Mark Davis, Zadie Oscier, David Montillo, Marco Trentin, Livio Rosenquist, Richard Ghia, Paolo Barrientos, Jacqueline C. Kolitz, Jonathan E. Allen, Steven L. Rai, Kanti R. Stamatopoulos, Kostas Kipps, Thomas J. Neuberg, Donna Chiorazzi, Nicholas Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia |
title | Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia |
title_full | Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia |
title_fullStr | Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia |
title_full_unstemmed | Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia |
title_short | Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia |
title_sort | impact of the types and relative quantities of ighv gene mutations in predicting prognosis of patients with chronic lymphocytic leukemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315922/ https://www.ncbi.nlm.nih.gov/pubmed/35903706 http://dx.doi.org/10.3389/fonc.2022.897280 |
work_keys_str_mv | AT kaufmanmatthew impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT yanxiaojie impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT liwentian impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT ghiaemanuelam impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT langerakantonw impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT rassentilauraz impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT belessichrysoula impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT kayneile impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT davifrederic impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT byrdjohnc impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT pospisilovasarka impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT brownjenniferr impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT catherwoodmark impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT daviszadie impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT oscierdavid impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT montillomarco impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT trentinlivio impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT rosenquistrichard impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT ghiapaolo impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT barrientosjacquelinec impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT kolitzjonathane impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT allenstevenl impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT raikantir impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT stamatopouloskostas impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT kippsthomasj impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT neubergdonna impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia AT chiorazzinicholas impactofthetypesandrelativequantitiesofighvgenemutationsinpredictingprognosisofpatientswithchroniclymphocyticleukemia |